Indocyanine Green-Enhanced Thermotherapy for Retinoblastoma

dc.contributor.authorAl-Haddad, Christiane Elias
dc.contributor.authorAbdulaal, Marwan R.
dc.contributor.authorSaab, Raya H.
dc.contributor.authorBashshur, Ziad F.
dc.contributor.departmentOphthalmology
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:28Z
dc.date.available2025-01-24T12:08:28Z
dc.date.issued2015
dc.description.abstractPurpose: To report the outcome of pediatric patients with retinoblastoma refractory to traditional local therapy who were treated with indocyanine green (ICG)-enhanced thermotherapy. Materials and Methods: This is a retrospective review of a case series of 3 patients with bilateral retinoblastoma who were treated with ICG-enhanced thermotherapy after showing no response to conventional chemothermotherapy or transpupillary thermotherapy (TTT) alone noted on two consecutive examinations under anesthesia. Results: The 3 patients had had one eye enucleated previously due to advanced disease, and the remaining eye was diagnosed with a large tumor, which showed either a marginal or no response to systemic chemotherapy and TTT. Addition of ICG enhancement during the subsequent TTT session shrunk the tumor to a measurable size that could then be followed by TTT alone as a means of treatment. One patient had tumor recurrence, at which time additional TTT without ICG was successfully applied after the tumor size had decreased; ICG enhancement was then added whenever TTT alone provided no response. Conclusions: ICG enhancement with TTT led to a measurable tumor regression in lesions that had previously not been responsive to traditional chemothermotherapy or isolated TTT. Message: These tumors had shown a minimal to no response to previous TTT treatment. However, adding ICG resulted in a measurable regression even though the same TTT treatment parameters were applied. © 2014 S. Karger AG, Basel. Copyright: All rights reserved.
dc.identifier.doihttps://doi.org/10.1159/000368558
dc.identifier.eid2-s2.0-85050466589
dc.identifier.urihttp://hdl.handle.net/10938/31802
dc.language.isoen
dc.publisherS. Karger AG
dc.relation.ispartofOcular Oncology and Pathology
dc.sourceScopus
dc.subjectIndocyanine green
dc.subjectRetinoblastoma
dc.subjectThermotherapy
dc.subjectCarboplatin
dc.subjectEtoposide
dc.subjectTopotecan
dc.subjectVincristine
dc.subjectArticle
dc.subjectCancer chemotherapy
dc.subjectCase report
dc.subjectChild
dc.subjectClinical article
dc.subjectCryotherapy
dc.subjectEye enucleation
dc.subjectFemale
dc.subjectFollow up
dc.subjectHuman
dc.subjectInfant
dc.subjectLocal therapy
dc.subjectMale
dc.subjectMedical record review
dc.subjectPreschool child
dc.subjectRetrospective study
dc.subjectTranspupillary thermotherapy
dc.subjectTreatment duration
dc.subjectTreatment outcome
dc.subjectTumor recurrence
dc.subjectTumor thickness
dc.subjectTumor volume
dc.titleIndocyanine Green-Enhanced Thermotherapy for Retinoblastoma
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2015-10225.pdf
Size:
328.62 KB
Format:
Adobe Portable Document Format